Key Leukemia Therapeutics Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb (BMS)
- Pfizer Inc.
- Johnson & Johnson (Janssen)
- AbbVie Inc.
- Gilead Sciences (Kite Pharma)
- Amgen Inc.
- Merck & Co. (MSD)
- Sanofi
- GlaxoSmithKline (GSK)
- Bayer AG
- AstraZeneca
- Eli Lilly and Company
- Takeda Pharmaceutical (ex-Japan ops)
- Takeda Pharmaceutical
- Astellas Pharma
- Daiichi Sankyo
- Eisai Co., Ltd.
- Otsuka Holdings
The global leukemia therapeutics market is highly consolidated, with the presence of several key players competing to enhance their international presence. The major firms, such as Novartis, AbbVie, and Gilead, hold a maximum share. Key strategies opted by the companies include geographical expansion through the establishment of manufacturing hubs, such as Novartis invested in Japan and EU facilities to reduce production time. Furthermore, product enhancement, precision medicine innovations are also creating a positive market expansion across the world.
Below is the list of some prominent players in the industry:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Leukemia therapeutics market size was valued at USD 20.1 billion in 2025.
Leukemia therapeutics market size was valued at USD 20.1 billion in 2025 and is projected to reach USD 43.7 billion by the end of 2035, rising at a CAGR of 6.5% during the forecast period, i.e., 2026-2035.
North America is a key player in the leukemia therapeutics market, projected to register a significant share of 34.7% in 2035.
The major players in the market include Novartis AG, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb (BMS), Pfizer Inc., Johnson & Johnson (Janssen), AbbVie Inc., Gilead Sciences (Kite Pharma), Amgen Inc., Merck & Co. (MSD), Sanofi, GlaxoSmithKline (GSK), Bayer AG, AstraZeneca, Eli Lilly and Company, Takeda Pharmaceutical (ex-Japan ops), Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai Co., Ltd., Otsuka Holdings.
